Clinical trials located in

Alessandria

Alessandria city is located in Italy. Currently, 14 clinical trials are being conducted in this city.

Alessandria, located in the Piedmont region of Italy, is a city rich in history and culture. Founded in 1168, it was named after Pope Alexander III. The city is renowned for its military significance, particularly the Citadel of Alessandria, one of Europe’s most impressive fortresses. Alessandria is also famous for the Hat Festival, celebrating its historical hat-making industry. The city’s strategic position on the Tanaro River has historically made it a key trading and agricultural hub. Notably, Alessandria is the birthplace of the Italian confectionery company Ferrero.

  • CT-EU-00117196

    Clinical Trial for Finding the Best Dose of Clodronate for Painful Knee Osteoarthritis

    Howdy there, folks! This here clinical trial is aimin’ to find the best dose of a medicine called clodronate for treatin’ painful knee arthritis. It’s gonna be split into two parts.

    In the first part, they’ll have four groups of folks with knee arthritis. Three of them groups will get different doses of clodronate injected right into their knee once a week for four weeks. The fourth group will get a placebo, which is like a fake medicine. They’ll be keepin’ an eye on how safe and tolerable them different doses are.

    Once they figure out which dose works best without too many side effects, they’ll move on to the second part. In that part, they’ll have two groups – one gettin’ the best dose of clodronate from the first part, and the other gettin’ a placebo again. They’ll be checkin’ to see how effective and safe that best dose really is for helpin’ with knee arthritis pain.

    The main thing they’re lookin’ for is if the clodronate can reduce knee pain by at least 10 millimeters on a special pain scale called the Visual Analogue Scale, compared to the placebo group. They’ll be measurin’ that around 7 weeks into the study.

    So in a nutshell, they’re tryin’ to find the best and safest dose of clodronate for helpin’ folks with painful knee arthritis. It’s a two-part study, and they’ll be keepin’ a close eye on how well it works and how well it’s tolerated.

    Italy
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGreeceHungaryItalyNetherlandsPolandPortugalSpainSweden
  • Comparison of different drug combinations in the treatment of relapsed mantle cell lymphoma

    In this trial, Glofitamab will be tested on patients with mantle cell lymphoma that has either recurred or not responded to prior therapy. The effectiveness of this medicine will be compared to alternative treatments suggested by physicians, such as a rituximab and bendamustine mix or a combination of lenalidomide and rituximab. Participants will be asked questions about their physical and emotional well-being, ability to handle day-to-day responsibilities, cognitive function, social lifestyle, symptoms like tiredness, vomiting, pain, etc., and overall health condition and life quality.

    FranceItalySpainSwedenUnited Kingdom
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Radium-223 radiation vs. new hormone therapy in prostate cancer trial

    In this study, scientists are looking into two treatments for prostate cancer that has spread to the bone. One is a medicine called Radium-223 Dichloride or simply Xofigo which uses radiation to destroy cancer cells. The other is a new kind of treatment that stops hormones from working, as these hormones can sometimes help cancer grow. This new treatment is called Novel Anti-hormonal Therapy or NAH for short. The aim is to see which works better and to compare their safety profiles. Xofigo works by emitting a special type of radiation once it is injected into the body and absorbed by the bones. This radiation travels only a short distance, so it doesn’t harm healthy cells while killing cancerous ones. NAH, on the other hand, includes medications like abiraterone acetate (Zytiga) or enzalutamide (Xtandi) which are usually given to advanced prostate cancer patients. People taking part in this study will either receive Xofigo or NAH. Xofigo is given via an injection into a vein every 4 weeks for up to 6 months, while an oral form of NAH will be given daily until the disease progresses. Participants will be in this study for around 2 years, visiting the hospital or clinic every 2 weeks initially and then less often. There will be blood and urine tests and questionnaires about well-being and pain management.

    AustriaCzechiaFinlandFranceGermanyHungaryItalyPolandSpainUnited Kingdom
  • Evaluating treatment strategies for small-cell lung cancer: A clinical trial with lurbinectedin, irinotecan, and topotecan

    This is a large test the researchers are running to help people with a certain type of lung cancer (called Small-cell Lung Cancer) that’s come back after they’ve had one type of treatment that contains platinum. The researchers are using three different ways of giving medicine to see which is best. The first way is to give only lurbinectedin. The second way is to give lurbinectedin and irinotecan together. The third way is to let the doctor decide to use topotecan or irinotecan alone. People’s selection to these groups will be by chance.

    AustriaBelgiumBulgariaDenmarkFranceGermanyHungaryItalyPolandRomaniaSpainUnited Kingdom
  • Examining new dosing of belantamab for resistant multiple myeloma

    The study is called DREAMM-14 and is intended for people with a disease called multiple myeloma that does not respond to other treatments. Scientists are investigating various possible uses of a drug called belantamab mafodotin. They want to see if changing the dose of the drug or the frequency of its administration can fight the disease more effectively and cause fewer side effects. They will also look at changes in your vision and the condition of the cornea (the clear front part of the eye) on a scale of 0 to 4. This scale assesses the condition of the cornea and any changes in vision, with 0 being no change and 4 being a major change. Doctors will measure how many people experience corneal changes, how long they last, and whether the events are related to the amount of medication they take. They will also look at how the disease responds to the medicine and how long it takes to take treatment.

    FranceGermanyGreeceItalyPolandSpainUnited Kingdom
  • Study of new combined therapy for untreatable lung membrane cancer

    This study is testing a new treatment for pleural mesothelioma, a type of lung cancer. It compares a new drug, Volrustomig combined with carboplatin and pemetrexed, against drugs chosen by the researcher, which could include platinum, pemetrexed, nivolumab, or ipilimumab. The goal is to see which treatment works better and is safer. About 600 adults with advanced mesothelioma that can’t be removed by surgery will participate. The study will look at how long patients live with each treatment and other health factors.

    BelgiumDenmarkFranceGermanyItalyNetherlandsNorwayPolandSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Epcoritamab test in combination with lenalidomide and rituximab for adult lymphoma patients

    This study assesses the safety and performance of the drug epcoritamab, combined with lenalidomide and rituximab, in adults with Follicular Lymphoma, a frequently occurring B-cell cancer which often recurs despite current treatments. The test aims to monitor adverse side effects and changes in the disease’s activity in patients whose illness has relapsed or not responded to previous treatments. Approximately 500 adults around the world will receive the treatment as part of this study. They will be assigned to one of three treatment groups. Some may undergo heavier treatment than their current care standards. Their response to treatment will be regularly monitored through medical assessments, blood tests, side effects tracking, and questionnaires.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom

See more clinical trials in other cities in Italy:

.